Te Ahumairangi Investment Management Ltd Makes New $896,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Te Ahumairangi Investment Management Ltd recently acquired a new position in Regeneron Pharmaceuticals, purchasing 1,412 shares valued at about $896,000 during the first quarter.
• Regeneron has received mixed ratings from analysts, with a prevailing consensus of "Moderate Buy" and a target price of approximately $817.67.
• The company reported a quarterly earnings per share of $12.89, significantly exceeding analyst expectations of $8.43, along with a revenue of $3.68 billion for the quarter.

Te Ahumairangi Investment Management Ltd purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,412 shares of the biopharmaceutical company's stock, valued at approximately $896,000.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares during the period. Nuveen LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $343,764,000. Pacer Advisors Inc. grew its stake in shares of Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after purchasing an additional 390,374 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Regeneron Pharmaceuticals by 171.0% during the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock valued at $305,311,000 after acquiring an additional 303,785 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Regeneron Pharmaceuticals by 30.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after purchasing an additional 226,952 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded down $2.80 during mid-day trading on Tuesday, hitting $577.90. 1,017,915 shares of the company were exchanged, compared to its average volume of 1,102,281. The company has a 50 day moving average of $558.63 and a 200-day moving average of $586.30. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,192.54. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The stock has a market cap of $61.25 billion, a price-to-earnings ratio of 14.56, a price-to-earnings-growth ratio of 1.93 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the firm posted $11.56 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price on the stock. in a research report on Friday, August 1st. Citigroup reaffirmed a "buy" rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Redburn Atlantic raised Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Morgan Stanley restated an "overweight" rating and set a $761.00 target price (up from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Rothschild & Co Redburn initiated coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.